Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 11, 2010, Pages 729-734

  Inada, M ^a   Sato, M ^a   Morita, S ^a   Kitagawa, K ^a   Kawada, K ^a   Mitsuma, A ^a   Sawaki, M ^a   Fujita, K ^b   Ando, Y ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Excision repair cross complementation group 1 (ERCC1); Glutathione S transferases pi 1 (GSTP1); Neuropathy; Oxaliplatin; Polymorphism

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; GLUTATHIONE TRANSFERASE P1; OXALIPLATIN;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUROPATHY; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; RELIABILITY; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78649301135     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48729     Document Type: Article

References (12)

1. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007; 33: 9-23.
2. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008; 14: 1291-1295.
3. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998; 16: 309-316. (Pubitemid 28041614)
4. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001; 19: 4298-4304.
5. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol. 2000; 16: 555-560.
6. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000; 9: 843-847.
7. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK, Awasthi S, Awasthi YC. Naturally occurringhuman glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem. 1994; 224: 893-899. (Pubitemid 24288851)
8. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007; 25: 1247-1254.
9. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G, Christiani DC. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005; 11: 1534-1538. (Pubitemid 40315237)
10. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res. 2006; 12: 3050-3056.
11. Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 2009; 101: 530-535.
12. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, Cortes A, Barnadas A, Baiget M. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer. 2008; 99: 1050-1055.